Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Barrett Esophagus 3Stomach Neoplasms 2Rectal Neoplasms 2Pancreatic Neoplasms 2Colorectal Neoplasms 2Thyroid Nodule 1Recurrence 1Locally Advanced Pancreatic Cancer 1Liver Cirrhosis 1Inflammatory Bowel Diseases 1Hypertension, Portal 1Gastrointestinal Neoplasms 1Fibrosis 1Esophageal Neoplasms 1Colonic Neoplasms 1Cardiotoxicity 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Diagnostic Imaging × Gastrointestinal × Clear all
NCT06265272 2025-09-26

Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis

Massachusetts General Hospital

Recruiting
45 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡